vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and Monster Beverage (MNST). Click either name above to swap in a different company.
Monster Beverage is the larger business by last-quarter revenue ($2.1B vs $1.1B, roughly 1.9× Elanco Animal Health Inc). Monster Beverage runs the higher net margin — 21.1% vs -24.1%, a 45.2% gap on every dollar of revenue. On growth, Monster Beverage posted the faster year-over-year revenue change (17.6% vs 12.2%). Monster Beverage produced more free cash flow last quarter ($351.2M vs $46.0M). Over the past eight quarters, Monster Beverage's revenue compounded faster (5.9% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Monster Beverage Corporation is an American beverage company that manufactures energy drinks including Monster Energy, Relentless, Reign and Burn. The company was originally founded as Hansen's in 1935 in Southern California, originally selling juice products. The company renamed itself as Monster Beverage in 2012.
ELAN vs MNST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $2.1B |
| Net Profit | $-276.0M | $449.2M |
| Gross Margin | 51.5% | 55.5% |
| Operating Margin | -22.6% | 25.5% |
| Net Margin | -24.1% | 21.1% |
| Revenue YoY | 12.2% | 17.6% |
| Net Profit YoY | -3350.0% | 65.9% |
| EPS (diluted) | $-0.55 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.1B | $2.2B | ||
| Q2 25 | $1.2B | $2.1B | ||
| Q1 25 | $1.2B | $1.9B | ||
| Q4 24 | $1.0B | $1.8B | ||
| Q3 24 | $1.0B | $1.9B | ||
| Q2 24 | $1.2B | $1.9B | ||
| Q1 24 | $1.2B | $1.9B |
| Q4 25 | $-276.0M | $449.2M | ||
| Q3 25 | $-34.0M | $524.5M | ||
| Q2 25 | $11.0M | $488.8M | ||
| Q1 25 | $67.0M | $443.0M | ||
| Q4 24 | $-8.0M | $270.7M | ||
| Q3 24 | $364.0M | $370.9M | ||
| Q2 24 | $-50.0M | $425.4M | ||
| Q1 24 | $32.0M | $442.0M |
| Q4 25 | 51.5% | 55.5% | ||
| Q3 25 | 53.4% | 55.7% | ||
| Q2 25 | 57.5% | 55.7% | ||
| Q1 25 | 57.3% | 56.5% | ||
| Q4 24 | 50.9% | 55.3% | ||
| Q3 24 | 52.2% | 53.2% | ||
| Q2 24 | 58.2% | 53.6% | ||
| Q1 24 | 57.3% | 54.1% |
| Q4 25 | -22.6% | 25.5% | ||
| Q3 25 | -4.4% | 30.7% | ||
| Q2 25 | 2.0% | 29.9% | ||
| Q1 25 | 5.0% | 30.7% | ||
| Q4 24 | -5.0% | 21.0% | ||
| Q3 24 | 54.3% | 25.5% | ||
| Q2 24 | -2.7% | 27.7% | ||
| Q1 24 | 1.0% | 28.5% |
| Q4 25 | -24.1% | 21.1% | ||
| Q3 25 | -3.0% | 23.9% | ||
| Q2 25 | 0.9% | 23.1% | ||
| Q1 25 | 5.6% | 23.9% | ||
| Q4 24 | -0.8% | 14.9% | ||
| Q3 24 | 35.3% | 19.7% | ||
| Q2 24 | -4.2% | 22.4% | ||
| Q1 24 | 2.7% | 23.3% |
| Q4 25 | $-0.55 | — | ||
| Q3 25 | $-0.07 | — | ||
| Q2 25 | $0.02 | — | ||
| Q1 25 | $0.13 | — | ||
| Q4 24 | $-0.01 | — | ||
| Q3 24 | $0.73 | — | ||
| Q2 24 | $-0.10 | — | ||
| Q1 24 | $0.06 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $2.8B |
| Total DebtLower is stronger | $3.9B | — |
| Stockholders' EquityBook value | $6.5B | $8.3B |
| Total Assets | $13.4B | $10.0B |
| Debt / EquityLower = less leverage | 0.60× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $2.8B | ||
| Q3 25 | $505.0M | $2.6B | ||
| Q2 25 | $539.0M | $2.1B | ||
| Q1 25 | $487.0M | $1.9B | ||
| Q4 24 | $468.0M | $1.5B | ||
| Q3 24 | $490.0M | $1.6B | ||
| Q2 24 | $416.0M | $1.6B | ||
| Q1 24 | $345.0M | $3.6B |
| Q4 25 | $3.9B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | $199.1M | ||
| Q4 24 | $4.3B | $374.0M | ||
| Q3 24 | $4.4B | $748.8M | ||
| Q2 24 | $5.7B | $748.7M | ||
| Q1 24 | $5.8B | — |
| Q4 25 | $6.5B | $8.3B | ||
| Q3 25 | $6.7B | $7.7B | ||
| Q2 25 | $6.8B | $7.2B | ||
| Q1 25 | $6.4B | $6.5B | ||
| Q4 24 | $6.1B | $6.0B | ||
| Q3 24 | $6.5B | $5.8B | ||
| Q2 24 | $5.9B | $5.9B | ||
| Q1 24 | $6.1B | $8.6B |
| Q4 25 | $13.4B | $10.0B | ||
| Q3 25 | $13.6B | $9.6B | ||
| Q2 25 | $13.7B | $8.7B | ||
| Q1 25 | $12.9B | $8.2B | ||
| Q4 24 | $12.6B | $7.7B | ||
| Q3 24 | $13.3B | $8.1B | ||
| Q2 24 | $13.8B | $8.1B | ||
| Q1 24 | $14.0B | $10.1B |
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | 0.03× | ||
| Q4 24 | 0.70× | 0.06× | ||
| Q3 24 | 0.67× | 0.13× | ||
| Q2 24 | 0.96× | 0.13× | ||
| Q1 24 | 0.95× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $379.4M |
| Free Cash FlowOCF − Capex | $46.0M | $351.2M |
| FCF MarginFCF / Revenue | 4.0% | 16.5% |
| Capex IntensityCapex / Revenue | 5.4% | 1.3% |
| Cash ConversionOCF / Net Profit | — | 0.84× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $2.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $379.4M | ||
| Q3 25 | $219.0M | $745.1M | ||
| Q2 25 | $237.0M | $466.0M | ||
| Q1 25 | $-4.0M | $507.6M | ||
| Q4 24 | $177.0M | $461.7M | ||
| Q3 24 | $162.0M | $618.4M | ||
| Q2 24 | $200.0M | $436.3M | ||
| Q1 24 | $2.0M | $412.1M |
| Q4 25 | $46.0M | $351.2M | ||
| Q3 25 | $127.0M | $701.5M | ||
| Q2 25 | $180.0M | $434.6M | ||
| Q1 25 | $-69.0M | $478.5M | ||
| Q4 24 | $130.0M | $370.4M | ||
| Q3 24 | $120.0M | $571.4M | ||
| Q2 24 | $166.0M | $376.5M | ||
| Q1 24 | $-22.0M | $346.1M |
| Q4 25 | 4.0% | 16.5% | ||
| Q3 25 | 11.2% | 31.9% | ||
| Q2 25 | 14.5% | 20.6% | ||
| Q1 25 | -5.8% | 25.8% | ||
| Q4 24 | 12.7% | 20.4% | ||
| Q3 24 | 11.7% | 30.4% | ||
| Q2 24 | 14.0% | 19.8% | ||
| Q1 24 | -1.8% | 18.2% |
| Q4 25 | 5.4% | 1.3% | ||
| Q3 25 | 8.1% | 2.0% | ||
| Q2 25 | 4.6% | 1.5% | ||
| Q1 25 | 5.4% | 1.6% | ||
| Q4 24 | 4.6% | 5.0% | ||
| Q3 24 | 4.1% | 2.5% | ||
| Q2 24 | 2.9% | 3.1% | ||
| Q1 24 | 2.0% | 3.5% |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 1.42× | ||
| Q2 25 | 21.55× | 0.95× | ||
| Q1 25 | -0.06× | 1.15× | ||
| Q4 24 | — | 1.71× | ||
| Q3 24 | 0.45× | 1.67× | ||
| Q2 24 | — | 1.03× | ||
| Q1 24 | 0.06× | 0.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
MNST
| Monster Energy Drinks Segment | $1.2B | 57% |
| Sales Revenue Product Line | $905.5M | 42% |
| Strategic Brands Segment | $50.3M | 2% |
| Alcohol Brands Segment | $29.0M | 1% |
